STOCK TITAN
  1. Home
  2. Sec-filings
  3. FLGT
  4. [Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Fulgent Genetics Insider Sale: 548 Shares Sold to Cover RSU Taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock on 08/25/2025 to satisfy tax withholding from vested restricted stock units originally granted on February 23, 2023. The Form 4 shows 548 shares sold at a weighted-average price of $21.5016 (individual sale prices ranged from $21.46 to $21.57). After the sale, the reporting person beneficially owned 959,091 shares. The filing was submitted by attorney-in-fact Paul Kim on 08/26/2025.

Positive

  • Timely disclosure of insider sale consistent with Section 16 reporting requirements
  • Transaction tied to RSU tax withholding, indicating non-speculative motive for sale

Negative

  • None.

Insights

TL;DR: Routine insider sale to cover tax withholding; disclosure reflects standard compliance with Section 16.

The sale appears to be a non-discretionary, tax-withholding transaction tied to RSU vesting, not an open-market divestiture for liquidity. Reporting the transaction on Form 4 and providing a weighted-average price aligns with disclosure requirements. The size of the sale (548 shares) is immaterial relative to the remaining beneficial ownership of 959,091 shares, indicating no evident change in control or strategic shift.

TL;DR: Small, routine sale by an officer; unlikely to affect investor valuation or signal material insider sentiment.

The transaction was executed at a weighted-average price of $21.5016, within a narrow price range, and was explicitly for satisfying tax obligations on vested RSUs. Given the modest number of shares sold relative to total holdings, this disclosure is informational and does not constitute a material change to share ownership or corporate outlook.

Insider Gao Hanlin
Role Chief Scientific Officer
Sold 548 shs ($12K)
Type Security Shares Price Value
Sale Common Stock 548 $21.5016 $12K
Holdings After Transaction: Common Stock — 959,091 shares (Direct)
Footnotes (1)
  1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gao Hanlin
(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE
(Street)
EL MONTE CA 91731
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/25/2025 S 548(1) D $21.5016(2) 959,091 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.
2. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
/s/ Paul Kim as Attorney-in-Fact 08/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Gao Hanlin (FLGT) report on Form 4 dated 08/25/2025?

The filing reports the sale of 548 shares at a weighted-average price of $21.5016 to satisfy tax withholding from vested RSUs.

How many FLGT shares does the reporting person own after the transaction?

The reporting person beneficially owned 959,091 shares following the reported sale.

Why were the shares sold according to the Form 4 for FLGT?

The shares were sold to satisfy tax withholding obligations arising upon the vesting of restricted stock units granted on February 23, 2023.

What price range were the FLGT shares sold at and what price was reported?

Shares were sold in multiple transactions at prices ranging from $21.46 to $21.57; the reported weighted-average price is $21.5016.

Who signed the Form 4 for this FLGT filing?

The Form 4 was signed by /s/ Paul Kim as Attorney-in-Fact on behalf of the reporting person on 08/26/2025.